Skip to main content
Fig. 3 | World Journal of Surgical Oncology

Fig. 3

From: Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma

Fig. 3

Genomic mutation profiles of CD73 high/low groups. A The oncoplot showing the distribution of the top 30 frequently mutated genes in patients with low CD73/NT5E mRNA expression on the left (blue) and those with high NT5E mRNA expression on the right (red). B Bar plots showing the differentially mutated genes between CD73 high and low groups. Data were analyzed by the chi-square test. Comparison of NT5E mRNA expression (C) and CD73 protein expression (D) across four molecular subtypes identified in the FU-iCCA cohort. Data were analyzed by the Kruskal–Wallis H test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page